Barinthus Biotherapeutics (BRNS) Net Cash Flow (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Net Cash Flow came in at -$3.3 million in Q1 2026, up 77.79% YoY from -$1.9 million in Q1 2025, and up 21.91% on a QoQ basis from -$4.2 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Net Cash Flow (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Net Cash Flow data on file, last reported at -$3.3 million in Q1 2026.
- Quarterly Net Cash Flow rose 77.79% year-over-year to -$3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36.0 million (down 16.22% YoY) and the FY2025 annual result came in at -$47.6 million, down 71.89% from the prior year.
- Net Cash Flow grew to -$3.3 million in Q1 2026, from -$4.2 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $13.6 million in Q4 2024 to a low of -$20.0 million in Q2 2023.
- A 5-year average of -$9.0 million and a median of -$11.2 million in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow surged 379.25% — and 2023, when it slumped 213.33%.
- Tracing BRNS's Net Cash Flow over 5 years: stood at -$11.4 million in 2022, then plunged by 68.99% to -$19.3 million in 2023, then jumped by 170.55% to $13.6 million in 2024, then tumbled by 131.07% to -$4.2 million in 2025, then climbed by 21.91% to -$3.3 million in 2026.
- The last three Net Cash Flow figures came in at -$3.3 million (Q1 2026), -$4.2 million (Q4 2025), and -$10.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | -8.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.03 Mn |
| Jun 30, 2026 | -8.03 Mn |
| Mar 31, 2026 | -3.31 Mn |
| Mar 31, 2026 | -3.31 Mn |
| Dec 31, 2025 | -4.24 Mn |
| Dec 31, 2025 | -4.24 Mn |
| Sep 30, 2025 | -10.28 Mn |
| Sep 30, 2025 | -10.28 Mn |
| Jun 30, 2025 | -18.14 Mn |
| Jun 30, 2025 | -18.14 Mn |
| Mar 31, 2025 | -14.91 Mn |
| Mar 31, 2025 | -14.91 Mn |
| Dec 31, 2024 | 13.65 Mn |
| Dec 31, 2024 | 13.65 Mn |
| Sep 30, 2024 | -17.85 Mn |
| Sep 30, 2024 | -17.85 Mn |
| Jun 30, 2024 | -11.84 Mn |
| Jun 30, 2024 | -11.84 Mn |
| Mar 31, 2024 | -11.63 Mn |
| Mar 31, 2024 | -11.63 Mn |